PR from Dr. Tracy, emphasis mine.........
Monday July 9, 10:00 am Eastern Time
Press Release
SOURCE: NeuroInvestment
Neuro R&D Programs Reviewed By NeuroInvestment
INTERNET WIRE -- NeuroInvestment has released its mid-year issue, appraising how
neuropharmaceutical companies and their programs fared during the first half of 2001, and
previewing the second half. This year has seen advances in the scientific understanding of
neural stem cells and the disease process underlying Alzheimer's, but has been marred by the
failure of the new administration to place a priority on patients rather than politics. As a
result, stem cell research is being slowed in the US, just as drug reviews and approvals are
being hindered by a rudderless FDA. While IPO activity was nil, private financing has
continued to be available, and many of these companies now have strong cash positions, able
to set equitable partnership terms and look for attractive acquisitions. The contents of the
July issue include:
a) Potential merger and acquisition players and targets in the CNS sector for the rest of this
year.
b) Capsule reviews of 49 public and private CNS companies, including Axonyx,, Cephalon
(NASDAQ:CEPH - news), Cortex, Drug Abuse Sciences, Gliatech, Guilford
(NASDAQ:GLFD - news), Interneuron, NeoTherapeutics, Neurocrine Biosciences
(NASDAQ:NBIX - news), Pharmos, Prescient Neuropharma, StemCells, and Titan
(AMEX:TTP - news).
Upcoming issues include:
August 2001: 'The IPO Classes of 2002-5.' NeuroInvestment's first comprehensive
overview of private CNS companies, the fifty most promising privately held neuro-oriented
companies in the US and Europe. Over the next four years, the best of these companies will
go public, and this issue highlights those worth watching. Companies to be covered include:
AGY, Centaur, Cogent, Cognetix, D-Pharm, Drug Abuse Sciences, Inotek, Memory
Pharmaceuticals, MetaPhore, MitoKor, NeuralStem, NeuroMed, Pherin, and Targacept.
September 2001: 'Mild Cognitive Impairment'. With the greying of the population in the US
and Europe, companies are turning their attention to the loss of cognitive performance that
millions of 'boomers' begin to experience in their forties and fifties. Maintaining memory and
other intellectual functions for this group will become a high-profile drug development target.
Programs to be reviewed include those from Axonyx, Cortex, Memory Pharmaceuticals, and
Neurogen.
Recent NeuroInvestment issues have included:
April 2001: Small molecule drugs to stimulate regeneration: The use of small molecule drugs has become the most clinically
advanced avenue to regenerating damaged areas of the brain and spinal cord. Programs from American Biogenetic Sciences,
Boston Life Sciences, Guilford NeoTherapeutics, Vertex, and others, were appraised. NeoTherapeutics, was given a
comprehensive corporate review.
May 2001: A review of the developments in CNS cell implant programs. These cells include fetal cells, embryonic stem cells,
adult source stem cells, and differentiated cell types. Programs reviewed from Aegera, Cell Factors, Ceregene, Curis, Diacrin.
Geron, Layton, NeuralStem, NeuroNova, NsGene, ReNeuron, StemCells, Titan, TriStem
June 2001: A review of schizophrenia drug development programs from companies including Acadia, Arena, Aventis,
Bristol-Myers Squibb/Otsuka, Cortex, Dainippon, Knoll, Neurocrine Biosciences,.Novartis, Organon, Sanofi-Synthelabo,
Titan, Wyeth-Ayerst NeuroInvestment has set the standard for reviews of the CNS pharmaceutical industry since 1995, and is
the leading publisher of independent research information regarding companies specializing in the development of therapeutics
for neurological/psychiatric disorders. The NeuroInvestment 'A List' achieved a 2000 mean increase of 63%, following
increases of 74% in 1999 and 35% in 1998. NeuroInvestment is published monthly. Hardcopy and/or electronic delivery
available.
Subscription Rates: 3-month trial $130, Individual:1 year $420, 2 year $720. Institutional: 3-month trial $160, 1 year $590, 2
year $1020.. Outside the US/Canada add $30 for hardcopy airmail.
Contact: NeuroInvestment, P.O. Box 458, Rye, NH 03870; 603-964-9640; fax: 603-964-7561; e-mail:
neuroinv@neuroinv.com. Web Site: www.neuroinvestment.com.
Contact:
Dr. Harry M. Tracy
603-964-9640 |
